Replies to post #213216 on Biotech Values

[DewDiligence]

RVNC—The short answer on why EPVantage missed RT002 when compiling their list of top unpartnered biotech assets is that they’re applying an unduly high discount rate to the NPV due to the drug’s not yet having completed phase-3.

What EPVantage is missing, IMO, is that the RT002 phase-3 program in glabellar lines is much less likely to fail than a typical phase-3 program insofar as the MoA of botulinum toxin in facial aesthetics is reliable and well understood.

For related info, please see:

#msg-127654469
#msg-123290722
#msg-128312892
#msg-129352560
#msg-132203157
#msg-133799255
#msg-124555757